Core Insights - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, specifically for clinically proven kinase targets [3] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:00 a.m. PT [1] - A live webcast of the presentation will be available on the company's website and archived for 30 days [2] Company Overview - Nuvalent specializes in creating precisely targeted therapies aimed at overcoming the limitations of existing cancer treatments [3] - The company utilizes expertise in chemistry and structure-based drug design to develop innovative small molecules [3] - Nuvalent's pipeline includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3]